A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.
NCT05029622
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
66
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Precocious Puberty
Interventions
DRUG:
Triptorelin Pamoate
Sponsor
Ipsen